The modulatory action of C-Vx substance on the immune system in COVID-19

References

• Mouliou DS, Pantazopoulos I, Gourgoulianis KI. COVID-19 smart diagnosis in the emergency department: all-in in practice. Expert Rev Respir Med. 2022;16(3):263–272.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–399.
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Varga SM. The CD8 T cell response to respiratory virus infections. Front Immunol. 2018;9:678.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510.
   PubMed Web of Science ®Google Scholar
• Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541–543.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059–1063.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider Cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Pawlowski C, Puranik A, Bandi H, et al. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. Sci Rep. 2021;11(1):4741.
   PubMed Web of Science ®Google Scholar
• Soodejani M T, Basti M, Tabatabaei SM, et al. Measles, mumps, and rubella (MMR) vaccine and COVID-19: a systematic review. Int J Mol Epidemiol Genet. 2021;12(3):35–39.
   PubMedGoogle Scholar
• Huang J, Tao G, Liu J, et al. Current prevention of COVID-19: natural products and herbal medicine. Front Pharmacol. 2020;11:588508.
   PubMed Web of Science ®Google Scholar
• De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11(1):3434.
   PubMed Web of Science ®Google Scholar
• Tavukcuoglu E, Horzum U, Cagkan Inkaya A, et al. Functional responsiveness of memory T cells from COVID-19 patients. Cell Immunol. 2021;365:104363.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48):eabd2071. DOI:10.1126/sciimmunol.abd2071.
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Varga SM. Cytokines and CD8 T cell immunity during respiratory syncytial virus infection. Cytokine. 2020;133:154481.
   PubMed Web of Science ®Google Scholar
• Zuo W, Zhao X. Natural killer cells play an important role in virus infection control: antiviral mechanism, subset expansion and clinical application. Clin Immunol. 2021;227:108727.
   PubMed Web of Science ®Google Scholar
• Varchetta S, Mele D, Oliviero B, et al. Unique immunological profile in patients with COVID-19. Cell Mol Immunol. 2021;18(3):604–612.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wei X, Guan J, et al. COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol. 2020;218:108516.
   PubMed Web of Science ®Google Scholar
• Aktas E, Kucuksezer UC, Bilgic S, et al. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009;254(2):149–154.
   PubMed Web of Science ®Google Scholar
• Frasca F, Scordio M, Santinelli L, et al. Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. Eur J Immunol. 2022;52(7):1120–1128. doi:10.1002/eji.202249824.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061.
   PubMed Web of Science ®Google Scholar
• Califano D, Furuya Y, Roberts S, et al. IFN-γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. Mucosal Immunol. 2018;11(1):209–219.
   PubMed Web of Science ®Google Scholar
• Hawman DW, Meade-White K, Lewenthal S, et al. T-cells and interferon gamma are necessary for survival following Crimean-Congo hemorrhagic fever virus infection in mice. Microorganisms. 2021;9(2):279. DOI:10.3390/microorganisms9020279.
   PubMed Web of Science ®Google Scholar
• Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918–1921.
   PubMed Web of Science ®Google Scholar
• Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-γ receptor. Science. 1993;259(5102):1742–1745.
   PubMed Web of Science ®Google Scholar
• Leibson HJ, Hendriks W, Althage A, et al. Role of γ-interferon in antibody-producing responses. Nature. 1984;309(5971):799–801.
   PubMed Web of Science ®Google Scholar
• Sidman CL, Marshall JD, Schultz LD, et al. γ-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984;309(5971):801–804.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988;140(12):4245–4252.
   PubMed Web of Science ®Google Scholar
• Gadotti AC, de Castro Deus M, Telles JP, et al. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171.
   PubMed Web of Science ®Google Scholar
• Paquette SG, Banner D, Zhao Z, et al. Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS One. 2012;7(6):e38214.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006;16(2):126–133.
   PubMed Web of Science ®Google Scholar
• Mu X, Liu K, Li H, et al. Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19. Cell Mol Immunol. 2021;18(8):2057–2058.
   PubMed Web of Science ®Google Scholar
• Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771–5777.
   PubMed Web of Science ®Google Scholar
• Gelmez MY, Oktelik FB, Tahrali I, et al. Immune modulation as a consequence of SARS-CoV-2 infection. Front Immunol. 2022;13:954391, doi:10.3389/fimmu.2022.954391.
   PubMedGoogle Scholar